Use of PET/CT to evaluate response to therapy in lymphoma

Nenhuma Miniatura disponível
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2011
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
EDIZIONI MINERVA MEDICA
Autores
ZANONI, L.
FANTI, S.
Citação
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, v.55, n.6, p.633-647, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
F-18-FDG-PET is a well established standard procedure for most lymphoma subtypes. In particular the advantage of metabolic imaging stands in its strong predictivity in response. Indeed PET scan has been incorporated into revised response criteria for aggressive lymphomas and recommended to be performed at baseline and after therapy. At the same time, several ongoing clinical trials are investigating the value of treatment adaptation based on interim PET (PETi) results for Hodgkin Lymphoma (HL) and aggressive Non-Hodgkin Lymphoma (NHL). On the other hand, scientific literature provides limited detailed information regarding the numerous non aggressive NHL subtypes. Usually indolent NHL are typically less FDG avid, furthermore their long natural history and high incidence of recurrence decreases the clinical impact of a potential risk-adapted or response-adapted approach. We reviewed, from a nuclear medicine point of view and a clinical point of interest, evidence for the use of FDG-PET in monitoring early and end treatment response.
Palavras-chave
Positron-emission tomography, Tomography, X-ray computed, Lymphoma, Medication therapy management
URI
https://observatorio.fm.usp.br/handle/OPI/23547
Referências
  1. Advani R, 2007, J CLIN ONCOL, V25, P3902, DOI 10.1200/JCO.2007.11.9867
  2. Andre M, 2011, ADV HEMATOL, V2011
  3. Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403
  4. Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311
  5. Herrmann K, 2007, CLIN CANCER RES, V13, P3552, DOI 10.1158/1078-0432.CCR-06-3025
  6. Weiler-Sagie M, 2010, J NUCL MED, V51, P25, DOI 10.2967/jnumed.109.067892
  7. Itti E, 2010, J NUCL MED, V51, P1857, DOI 10.2967/jnumed.110.080556
  8. Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085
  9. Torizuka T, 2004, EUR J NUCL MED MOL I, V31, P22, DOI 10.1007/s00259-003-1333-8
  10. Farrell K, 2011, HISTOPATHOLOGY, V58, P15, DOI 10.1111/j.1365-2559.2010.03705.x
  11. Hutchings M, 2006, BLOOD, V107, P52, DOI 10.1182/blood-2005-06-2252
  12. Straus DJ, 2011, BLOOD, V117, P5314, DOI 10.1182/blood-2010-10-314260
  13. Terasawa T, 2009, J CLIN ONCOL, V27, P1906, DOI 10.1200/JCO.2008.16.0861
  14. Juweid ME, 2007, J CLIN ONCOL, V25, P571, DOI 10.1200/JCO.2006.08.2305
  15. Yoo C, 2011, ANN HEMATOL, V90, P797, DOI 10.1007/s00277-010-1135-6
  16. Dupuis J, 2009, ANN ONCOL, V20, P503, DOI 10.1093/annonc/mdn671
  17. Zinzani PL, 1999, ANN ONCOL, V10, P1181, DOI 10.1023/A:1008327127033
  18. Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104
  19. Hutchings M, 2005, ANN ONCOL, V16, P1160, DOI 10.1093/annonc/mdi200
  20. Casasnovas RO, 2011, BLOOD, V118, P37, DOI 10.1182/blood-2010-12-327767
  21. Spaepen K, 2001, BRIT J HAEMATOL, V115, P272, DOI 10.1046/j.1365-2141.2001.03169.x
  22. Fruchart C, 2006, LEUKEMIA LYMPHOMA, V47, P2547, DOI 10.1080/10428190600942959
  23. Picardi M, 2007, LEUKEMIA LYMPHOMA, V48, P1721, DOI 10.1080/10428190701559140
  24. Barrington SF, 2010, EUR J NUCL MED MOL I, V37, P1824, DOI 10.1007/s00259-010-1490-5
  25. Engert A, 2010, NEW ENGL J MED, V363, P640, DOI 10.1056/NEJMoa1000067
  26. Kobe C, 2008, BLOOD, V112, P3989, DOI 10.1182/blood-2008-06-155820
  27. Spaepen K, 2001, J CLIN ONCOL, V19, P414
  28. Engert A, 2003, J CLIN ONCOL, V21, P3601, DOI 10.1200/JCO.2003.03.023
  29. Mikhaeel NG, 2005, ANN ONCOL, V16, P1514, DOI 10.1093/annonc/mdi272
  30. Cheson BD, 1999, J CLIN ONCOL, V17, P1244
  31. Herrmann K, 2011, J NUCL MED, V52, P690, DOI 10.2967/jnumed.110.084566
  32. Mikhaeel NG, 2000, LEUKEMIA LYMPHOMA, V39, P543, DOI 10.3109/10428190009113384
  33. Girinsky T, 2006, RADIOTHER ONCOL, V79, P270, DOI 10.1016/j.radonc.2006.05.015
  34. Cerci JJ, 2010, J NUCL MED, V51, P1337, DOI 10.2967/jnumed.109.073197
  35. Engles JM, 2006, J NUCL MED, V47, P603
  36. Graf N, 2008, MOL IMAGING BIOL, V10, P349, DOI 10.1007/s11307-008-0162-3
  37. Gallamini A, 2007, J CLIN ONCOL, V25, P3746, DOI 10.1200/JCO.2007.11.6525
  38. Kostakoglu L, 2002, J NUCL MED, V43, P1018
  39. Meignan M, 2009, LEUKEMIA LYMPHOMA, V50, P1257, DOI 10.1080/10428190903040048
  40. Itti E, 2009, J NUCL MED, V50, P527, DOI 10.2967/jnumed.108.057703
  41. Brepoels L, 2007, LEUKEMIA LYMPHOMA, V48, P1522, DOI 10.1080/10428190701474365
  42. Haioun C, 2005, BLOOD, V106, P1376, DOI 10.1182/blood-2005-01-0272
  43. Le Roux PY, 2011, EUR J NUCL MED MOL I, V38, P1064, DOI 10.1007/s00259-011-1741-0
  44. Eich HT, 2010, J CLIN ONCOL, V28, P4199, DOI 10.1200/JCO.2010.29.8018
  45. Gallamini A, 2006, HAEMATOL-HEMATOL J, V91, P475
  46. de Wit M, 2001, ANN ONCOL, V12, P29
  47. Barnes JA, 2011, ANN ONCOL, V22, P910, DOI 10.1093/annonc/mdq549
  48. Brepoels L, 2007, LEUKEMIA LYMPHOMA, V48, P1539, DOI 10.1080/10428190701422414
  49. Cheson BD, 2011, J CLIN ONCOL, V29, P1844, DOI 10.1200/JCO.2010.32.5225
  50. Weihrauch MR, 2001, BLOOD, V98, P2930, DOI 10.1182/blood.V98.10.2930
  51. LISTER TA, 1989, J CLIN ONCOL, V7, P1630
  52. Cashen AF, 2011, J NUCL MED, V52, P386, DOI 10.2967/jnumed.110.082586
  53. Juweid ME, 2011, METHODS MOL BIOL, V727, P1, DOI 10.1007/978-1-61779-062-1_1
  54. Spaepen K, 2002, ANN ONCOL, V13, P1356, DOI 10.1093/annonc/mdf256
  55. Sher DJ, 2009, ANN ONCOL, V20, P1848, DOI 10.1093/annonc/mdp071
  56. Han HS, 2009, ANN ONCOL, V20, P309, DOI 10.1093/annonc/mdn629
  57. Jerusalem G, 1999, BLOOD, V94, P429
  58. Lin C, 2007, J NUCL MED, V48, P1626, DOI 10.2967/jnumed.107.042093
  59. Chihara D, 2011, INT J HEMATOL, V93, P502, DOI 10.1007/s12185-011-0822-y
  60. Terasawa T, 2008, J NUCL MED, V49, P13, DOI 10.2967/jnumed.107.039867
  61. Okada M, 2010, RADIOGRAPHICS, V30, P939, DOI 10.1148/rg.304095150
  62. Aleman BMP, 2003, J CLIN ONCOL, V21, P3431, DOI 10.1200/JCO.2003.07.131
  63. Gallamini A, 2009, LEUKEMIA LYMPHOMA, V50, P1761, DOI 10.3109/10428190903308072
  64. Jerusalem G, 2000, HAEMATOLOGICA, V85, P613
  65. Dann EJ, 2010, HAEMATOL-HEMATOL J, V95, P1198, DOI 10.3324/haematol.2009.016105
  66. Aridgides P, 2011, ADV HEMATOL, V2011
  67. Armitage JO, 2011, CURR HEMATOL MALIG R, V6, P155, DOI 10.1007/s11899-011-0092-z
  68. Bartlett NL, 2010, HEMATOL-AM SOC HEMAT, P108, DOI 10.1182/asheducation-2010.1.108
  69. Basu S, 2009, EUR J NUCL MED MOL I, V36, P2089, DOI 10.1007/s00259-009-1296-5
  70. Bishu S, 2007, LEUKEMIA LYMPHOMA, V48, P1548, DOI 10.1080/10428190701422059
  71. Brepoels L, 2009, J NUCL MED, V50, P1102, DOI 10.2967/jnumed.109.062208
  72. Buck AK, 2007, EUR J NUCL MED MOL I, V34, P1775, DOI 10.1007/s00259-007-0452-z
  73. Cazaentre T, 2010, EUR J NUCL MED MOL I, V37, P494, DOI 10.1007/s00259-009-1275-x
  74. Delbeke D, 2009, ONCOLOGIST, V14, P30, DOI 10.1634/theoncologist.2009-S2-30
  75. FOX KA, 1987, J CLIN ONCOL, V5, P38
  76. Gallamini A, 2011, LEUKEMIA LYMPHOMA, V52, P583, DOI 10.3109/10428194.2010.551162
  77. Hutchings M, 2009, EXPERT REV HEMATOL, V2, P261, DOI [10.1586/ehm.09.21, 10.1586/EHM.09.21]
  78. Hutchings M, 2009, J NUCL MED, V50, p21S, DOI 10.2967/JNUMED.108.057190
  79. Juweid ME, 2002, EUR J NUCL MED S1, V29, pS264
  80. Juweid ME, 2005, J CLIN ONCOL, V23, P4652, DOI 10.1200/JCO.2005.01.891
  81. Kasamon YL, 2011, ADV HEMATOL
  82. Kostakoglu L, 2006, CANCER, V107, P2678, DOI 10.1002/cncr.22276
  83. Lopci E, 2010, ANN ONCOL, V21, P1877, DOI 10.1093/annonc/mdq024
  84. Lopci E, 2010, Q J NUCL MED MOL IM, V54, P436
  85. Maffione AM, 2009, CLIN NUCL MED, V34, P777, DOI 10.1097/RLU.0b013e3181b81c34
  86. Maisey NR, 2000, EUR J CANCER, V36, P200, DOI 10.1016/S0959-8049(99)00249-X
  87. Markova J, 2011, LEUK LYMPHOMA 0824
  88. Markova J, 2009, ANN ONCOL, V20, P1270, DOI 10.1093/annonc/mdn768
  89. Meignan M, 2010, EUR J NUCL MED MOL I, V37, P1821, DOI 10.1007/s00259-010-1546-6
  90. Michallet AS, 2010, CURR OPIN ONCOL, V22, P414, DOI 10.1097/CCO.0b013e32833d5905
  91. Mikhaeel NG, 2002, ANN ONCOL, V13, P21
  92. Murawski N, 2010, EXPERT REV ANTICANC, V10, P387, DOI [10.1586/era.09.170, 10.1586/ERA.09.170]
  93. Ria R, 2011, J NUCL MED, V52, P891, DOI 10.2967/jnumed.110.084376
  94. Storto G, 2010, RADIOLOGY, V254, P245, DOI 10.1148/radiol.09090603
  95. Yahalom J, 2007, LEUKEMIA LYMPHOMA, V48, P1667, DOI 10.1080/10428190701606875
  96. Zijlstra JM, 2006, HAEMATOL-HEMATOL J, V91, P522
  97. Zinzani PL, 2011, CANCER-AM CANCER SOC, V117, P1010, DOI 10.1002/cncr.25579
  98. Zinzani PL, 2006, ANN ONCOL, V17, P1296, DOI 10.1093/annonc/mdl122

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros